iSONEP
Phase 3Biologic
iSONEP is one of 51 biologic programs targeting Spinal Cord Injury. It is currently in Phase 3.
2
Indications
12
Total Trials
2
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
65 competitors in Spinal Cord Injury
#DrugCompanyPhaseTrials
1Zometa
PfizerApproved
Cialis
Eli LillyApproved
Keppra
UCBApproved
Lioresal
NovartisApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Calciferol
Jazz PharmaceuticalsApproved
Prolia
OOrganon and Co
Approved
Botox
RRevance Therapeutics, Inc.
Approved
Proair HFA
GGlaxo Dba Glaxosmithkline
Approved
Bendopa
MMerz North America, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Age-Related Macular Degeneration2 trials
Randomized1 trial
Elderly Patients1 trial
Dosage of Epidural Morphine in Elderly Patients
Completed·—·Phase 4·NCT04316871·96 enrolled
6 more indications
Spinal Cord Injury1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for iSONEP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details